STOCK TITAN

SciSparc Ltd. Ordinary Shares - SPRC STOCK NEWS

Welcome to our dedicated page for SciSparc Ltd. Ordinary Shares news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc Ltd. Ordinary Shares stock.

SciSparc Ltd. (Nasdaq: SPRC) is a specialty clinical-stage pharmaceutical company dedicated to developing innovative therapies for disorders of the central nervous system. With a strong focus on cannabinoid pharmaceuticals, the company is engaged in pioneering drug development programs targeting conditions like Tourette Syndrome, Alzheimer's disease, pain, Autism Spectrum Disorder (ASD), and status epilepticus using both THC and non-psychoactive CBD.

The company's robust pipeline includes SCI-110 for treating Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain management, and SCI-210 for ASD and status epilepticus. Recently, SciSparc enrolled the first patient in its clinical trial for SCI-210, aimed at treating children with ASD.

In addition to drug development, SciSparc owns a subsidiary focused on online sales of hemp-based wellness products, including gummies, oils, capsules, and creams.

SciSparc's commitment to scientific excellence is highlighted by its collaborations and partnerships. For example, its venture with MitoCareX Bio leverages advanced computational platforms for cancer drug discovery, targeting mitochondrial SLC25 proteins.

The company is also actively expanding its intellectual property portfolio, with recent patents granted in the U.S., Canada, and Europe. These patents cover innovative compositions that enhance the therapeutic effects of cannabinoids while reducing side effects, thereby boosting its competitive edge globally.

Latest News:

  • March 8, 2024: First patient enrolled in ASD clinical trial for SCI-210.
  • March 12, 2024: MitoCareX Bio screens millions of small molecules for potential anti-cancer treatments.
  • March 14, 2024: First patient dosed in SCI-210 ASD trial.
  • March 18, 2024: Granted Canadian patent for cannabinoid and n-acylethanolamine compositions.
  • March 27, 2024: Clearmind partnership leads to multiple new patent applications.
  • May 31, 2024: European Patent Office grants patent for antimicrobial compositions.
Rhea-AI Summary

SciSparc Ltd. (Nasdaq: SPRC) has announced a $1 million share buyback program, aimed at enhancing shareholder value. The program will require court approval in Israel and is contingent upon the formal approval of financial statements for the six months ending June 30, 2022. The company is engaged in developing cannabinoid-based therapies targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder. This move reflects SciSparc's commitment to delivering shareholder returns amidst ongoing clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
buyback management
-
Rhea-AI Summary

SciSparc Ltd. (Nasdaq: SPRC) has announced the successful development of its drug candidate SCI-110 for an upcoming Phase IIb trial targeting Tourette Syndrome (TS). The company received ethics committee approvals from institutions in Germany and Israel for the study. SCI-110 aims to provide a safe treatment option for patients with limited alternatives. The multinational study will evaluate the drug's efficacy and safety in adults aged 18-65, focusing on tic severity changes. The trial's launch awaits further regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) has received approval from the Soroka University Ethics Committee to conduct a clinical trial for its proprietary drug SCI-210, targeting Autism Spectrum Disorder (ASD). This trial aims to evaluate the safety, tolerability, and efficacy of SCI-210, a combination of cannabidiol and CannAmide™, compared to CBD monotherapy in 60 children over 20 weeks. The approval marks a significant milestone for SciSparc in its pursuit of developing effective treatments for pediatric patients with limited options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
Rhea-AI Summary

SciSparc Ltd. (Nasdaq: SPRC) announced the appointment of Prof. Ciro Leonardo Pierri as a special advisor for MitoCareX Bio Ltd., its new joint venture focused on drug development for cancers and infectious diseases. Prof. Pierri, a biochemist from the University of Bari, Italy, brings expertise in structural biology and molecular modeling. The JV aims to explore mitochondrial carriers' roles in disease treatment, building on successful proof-of-concept experiments in the UK. SciSparc is engaged in cannabinoid-based drug development, targeting conditions like Tourette syndrome and Alzheimer’s disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (Nasdaq: SPRC) announced a review of potential strategic transactions aimed at maximizing shareholder value. The board is considering various options, including investments, acquisitions, partnerships, or licensing its technologies. CEO Oz Adler highlighted the company's strong cash position, allowing for exploration of external alternatives while continuing its existing business strategy. The firm remains focused on developing treatments for central nervous system disorders, including Alzheimer’s and Tourette syndrome, while adhering to FDA guidelines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
management
-
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) announced positive initial pre-clinical results for a treatment for cocaine addiction using MEAI, a novel psychedelic molecule from Clearmind Medicine Inc. (CSE: CMND). The collaborative provisional patent application was filed to explore treatment potential based on SciSparc's CannAmide™ compound and Clearmind's MEAI. The trials indicated that MEAI could reduce cocaine's reward effects in rats, presenting a potential breakthrough in cocaine addiction treatment. The study was conducted by Professor Gal Yadid at Bar Ilan University.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
none
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) has completed a $10 million private placement priced at-the-market, facilitated by Aegis Capital Corp. as the exclusive placement agent. The company is focused on developing cannabinoid-based pharmaceuticals, including SCI-110 for Tourette syndrome and SCI-160 for pain management. These projects aim to target various ailments such as Alzheimer's and autism. The private placement reflects investor confidence in SciSparc's innovative drug development pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) has announced a collaboration with Clearmind Medicine Inc. to file a provisional patent for a treatment targeting cocaine addiction. This involves a combination of SciSparc's CannAmide™ and Clearmind's MEAI, addressing the significant issue of cocaine addiction affecting over 1.3 million Americans. Current statistics highlight more than 350,000 hospital visits annually linked to cocaine use and around 16,000 overdose deaths. The collaboration aims to explore potential therapeutic solutions for addictions, with ongoing efforts to strengthen their partnership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) announced the closure of a private placement, securing approximately $10 million in gross proceeds from a single healthcare-focused institutional investor. The company issued 3,546,100 units at a price of $2.82 per unit, consisting of one ordinary share and two non-tradable warrants, each exercisable for an ordinary share at $2.57 for a total of 7,092,200 shares underlying the warrants. The warrants have a term of five years. Aegis Capital Corp. acted as the exclusive placement agent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) has announced a collaboration with Polyrizon Ltd. to develop an innovative pain treatment using SciSparc's SCI-160 platform combined with Polyrizon's Trap and TargetTM technology. The goal is to create a proprietary intranasal formulation that maintains effective SCI-160 concentrations in the brain. SciSparc will pay up to $2,550,000 in development fees, plus royalties on product sales. Previous pre-clinical trials demonstrated SCI-160's efficacy and safety in pain management, with results comparable to high-dose morphine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
none

FAQ

What is the current stock price of SciSparc Ltd. Ordinary Shares (SPRC)?

The current stock price of SciSparc Ltd. Ordinary Shares (SPRC) is $0.2133 as of December 20, 2024.

What is the market cap of SciSparc Ltd. Ordinary Shares (SPRC)?

The market cap of SciSparc Ltd. Ordinary Shares (SPRC) is approximately 2.2M.

What does SciSparc Ltd. do?

SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders.

What are SciSparc's main drug development programs?

SciSparc's main programs include SCI-110 for Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain, and SCI-210 for ASD and status epilepticus.

What recent achievements has SciSparc announced?

Recent achievements include enrolling the first patient in the SCI-210 ASD trial, obtaining a Canadian patent, and expanding partnerships with MitoCareX Bio and Clearmind.

What products does SciSparc offer online?

SciSparc's subsidiary sells hemp-based products like gummies, oils, capsules, and creams on Amazon Marketplace.

Where is SciSparc Ltd. based?

SciSparc Ltd. is based in Tel Aviv, Israel.

Is SciSparc involved in cancer research?

Yes, through its venture MitoCareX Bio, SciSparc is involved in cancer drug discovery targeting mitochondrial SLC25 proteins.

What patents has SciSparc recently secured?

SciSparc has recently secured patents in the U.S., Canada, and Europe for cannabinoid compositions and antimicrobial methods.

Who leads SciSparc Ltd.?

SciSparc Ltd. is led by a team of experienced senior executives and scientists.

What is SCI-210?

SCI-210 is a proprietary treatment combining cannabidiol (CBD) and CannAmide™ for Autism Spectrum Disorder and status epilepticus.

What is the significance of SciSparc's new patents?

The new patents strengthen SciSparc's intellectual property portfolio and enhance its position in the global pharmaceutical market.

SciSparc Ltd. Ordinary Shares

Nasdaq:SPRC

SPRC Rankings

SPRC Stock Data

2.17M
10.36M
0%
1.73%
2.51%
Biotechnology
Healthcare
Link
United States of America
Tel Aviv